Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-18 (tipranks.com)
Biogen, Stoke Therapeutics announce zorevunersen commercialization agreement - TipRanks.com
Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential disease modifying medic...
Read more
2025-01-31 (mmm-online.com)
Rx Rundown: Merck, Biogen, Pfizer and more - MM+M - Medical Marketing and Media
Check out this week’s medical marketing news, dealmaking and industry chatter.
Read more
2025-01-17 (mmm-online.com)
Rx Rundown: Johnson & Johnson, Eli Lilly, the FDA and more
Check out this week’s medical marketing news, dealmaking and industry chatter.
Read more
2025-01-07 (iletisimdunyasi.com.tr)
Company news from A1 Capital - Communication World
Istanbul, January 6 (Hibia) - A1 Capital, GEN, Biogen Inc. announced that it signed a transition agreement to end its distributorship relationship with the company.
Read more
2025-01-07 (pazarlamadunyasi.com.tr)
Company news from A1 Capital - Pazarlama Dunyasi
Istanbul, January 6 (Hibia) - A1 Capital, GEN, Biogen Inc. announced that it signed a transition agreement to end its distributorship relationship with the company.
Read more
2025-01-06 (paraajansi.com.tr)
PDP Bulletin Company News Share Buybacks January 6
PDP Bulletin Company News Share Buybacks 6 January. Notable company news and details in the KAP bulletin...
Read more
2024-10-31 (thepharmaletter.com)
Up to $1.45 billion on the line in Biogen and Neomorph deal
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases.
Read more
2024-10-31 (biospectator.com)
Biogen signs 1.45 billion won deal with Neomorph, “Molecular adhesive enters the war”
Reporter Jeong Ji-yoon, Biospectator
Read more
2024-10-30 (sdbn.org)
Biogen signs molecular glue deal, raises yearly projections – San Diego Biotechnology Network
Is 2024 the year of molecular glues? Biogen on Tuesday became the latest company to partner on the increasingly popular subject, teaming up with private San Diego biotech Neomorph. Biogen will pay Neomorph an undisclosed …
Read more
2024-09-27 (biospace.com)
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression
Read more
2024-08-13 (medtechdive.com)
Unilabs inks deal to sell C2N Alzheimer’s blood tests in Europe
C2N Diagnostics announced the partnership after recently receiving an investment from the Japanese drugmaker Eisai, which developed the Alzheimer’s drug Leqembi with Biogen.
Read more
2024-08-12 (realtid.se)
Xbrane Biopharma must out-license drugs to secure financing
Biotech company Xbrane Biopharma has begun a process of out-licensing Xdivane and XB003 to secure financing until the second quarter of 2025, when it is expected to reach positive operating cash flow. It appears from a press release.
Read more